![]() Patients (N = 443) with stage II to III TNBC received paclitaxel 80 mg/m 2 once per week (wP) for 12 weeks, followed by doxorubicin plus cyclophosphamide once every 2 weeks (ddAC) for four cycles, and were randomly assigned to concurrent carboplatin (area under curve 6) once every 3 weeks for four cycles and/or bevacizumab 10 mg/kg once every 2 weeks for nine cycles. Hahn, University of Chicago Medical Center, Chicago, IL. Pluard, Washington University-St Louis Medical Center, St Louis, MO George Somlo, City of Hope Comprehensive Cancer Center, Duarte Deborah Collyar, Patient Advocates in Research, Danville, CA and Olwen M. Winer, Dana-Farber Cancer Institute, Boston, MA Timothy J. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY Sara M. Port, Mount Sinai Medical Center Clifford A. Kuzma, Southeast Cancer Control Consortium, Winston-Salem, NC Baljit Singh, New York University Medical Center Elisa R. No Archives Categories.Ĭirrincione, Alliance Statistical Center, Durham Charles S. Carey, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill Constance T. Berry, University of Texas MD Anderson Cancer Center, Houston, TX Charles M. Sikov, Miriam Hospital and Alpert Medical School of Brown University, Providence, RI Donald A.
0 Comments
Leave a Reply. |